Peter J. Pitts
Lawmakers’ efforts to ensure that patients know about financial ties between drug firms and healthcare providers are understandable. But such restrictions should be limited to a company’s marketing efforts -- not its activities in medical research. (Full article: 509 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
